BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

Fudan University develops pan-coronavirus inhibitor   A team led by Fudan University researchers has developed a lipopeptide-based pan-coronavirus inhibitor of viral membrane fusion. Described in a preprint on the bioRxiv server, the lipopeptide binds the...
BC Extra | Nov 22, 2019
Preclinical News

Nov. 21 Preclinical Quick Takes: Excision applies CRISPR editing to herpes, John Cunningham viruses; plus Caribou, Oligomerix, Kymab and Gladstone-Boston Univer

Excision targets CRISPR to herpes, JC viruses  Excision BioTherapeutics Inc. and collaborators at Temple University presented a pair of posters at the International Symposium on NeuroVirology meeting in Atlanta showing CRISPR-Cas9 gene editing could treat...
BC Innovations | Sep 25, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

As most gene editing companies remain laser-focused on the well-studied CRISPR-Cas9 system marred in IP disputes, a new study from Locus co-founders shows that an entirely different type of CRISPR system can tune gene expression...
BC Innovations | May 16, 2019
Emerging Company Profile

SNIPR: Turning CRISPR into a microbiome suicide

SNIPR is using CRISPR to target specific bacteria to fight infection or modulate the immune system. Growing interest in CRISPR for mammalian cells and microbiome-focused therapeutics led the company's co-founders, Christian Grøndahl, Morten Sommer and...
BC Week In Review | Jan 4, 2019
Company News

Janssen, Locus partner on CRISPR-Cas3 bacteriophages

Janssen Pharmaceuticals Inc. partnered with Locus Biosciences Inc. (Morrisville, N.C.) to develop and commercialize CRISPR-Cas3-enhanced bacteriophage therapies against two bacterial pathogens to treat infections of the respiratory tract and other organ systems. Locus will receive...
BC Innovations | Oct 4, 2018
Tools & Techniques

No crisp upper hand in CRISPR

While the most recent ruling in the ongoing CRISPR IP battle maintained the Broad Institute’s dominant patent position in the U.S., University of California Berkeley’s dominant position in Europe, coupled with the looming possibility of...
BC Week In Review | Jul 20, 2018
Company News

Cas3 antimicrobial company acquires Epibiome tech

Locus Biosciences Inc. (Research Triangle Park, N.C.) acquired a phage discovery platform from fellow antibacterial company EpiBiome Inc. (South San Francisco, Calif.) in an all-stock deal. Locus declined to disclose financial terms. Locus launched in...
BC Extra | Jul 17, 2018
Company News

Cas3 antimicrobial company acquires EpiBiome tech

Locus Biosciences Inc. (Research Triangle Park, N.C.) acquired a phage discovery platform from fellow antibacterial company EpiBiome Inc. (South San Francisco, Calif.) in an all-stock deal. Locus declined to disclose financial terms. Locus launched in...
BC Week In Review | Nov 17, 2017
Financial News

Venture roundup: ImmusanT, Locus

On Nov. 14, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round...
BC Extra | Nov 15, 2017
Financial News

Venture Roundup: ImmusanT, Locus

On Tuesday, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round led...
Items per page:
1 - 10 of 12